Theravance Biopharma, Inc. Earnings Per Share (Diluted)
Theravance Biopharma, Inc. (TBPH) reported Earnings Per Share (Diluted) of -$0.11 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-11
- Theravance Biopharma, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.11, a 110.19% decline year-over-year.
- Theravance Biopharma, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.10.
- Theravance Biopharma, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was $1.15.
- Theravance Biopharma, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was $0.07.
- Theravance Biopharma, Inc. earnings per share, diluted for fiscal 2025 was $2.06.
- Theravance Biopharma, Inc. earnings per share, diluted for fiscal 2024 was -$1.15.
- Theravance Biopharma, Inc. earnings per share, diluted for fiscal 2023 was -$1.00, a 108.44% decline from fiscal 2022.
- Theravance Biopharma, Inc. earnings per share, diluted for fiscal 2022 was $11.85.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$0.11 10-Q · filed 2026-08-11 | -$0.21 10-Q · filed 2026-08-11 | $0.96 derived: net income ÷ weighted average shares · filed 2026-08-11 | $1.03 derived: net income ÷ weighted average shares · filed 2026-08-11 | |
| 2026-03-31 | -$0.10 10-Q · filed 2026-05-07 | $1.07 derived: net income ÷ weighted average shares · filed 2026-05-07 | $1.15 derived: net income ÷ weighted average shares · filed 2026-05-07 | $2.21 derived: net income ÷ weighted average shares · filed 2026-08-11 | |
| 2025-12-31 | $1.15 10-K · filed 2026-03-23 | $1.23 derived: net income ÷ weighted average shares · filed 2026-03-23 | $2.30 derived: net income ÷ weighted average shares · filed 2026-08-11 | $2.06 10-K · filed 2026-03-23 | |
| 2025-09-30 | $0.07 10-K · filed 2026-03-23 | $1.14 derived: net income ÷ weighted average shares · filed 2026-08-11 | $0.88 10-Q · filed 2025-11-12 | $0.58 derived: net income ÷ weighted average shares · filed 2026-08-11 | |
| 2025-06-30 | $1.08 10-Q · filed 2026-08-11 | $0.81 10-Q · filed 2026-08-11 | $0.52 derived: net income ÷ weighted average shares · filed 2026-08-11 | $0.26 derived: net income ÷ weighted average shares · filed 2026-08-11 | |
| 2025-03-31 | -$0.27 10-Q · filed 2026-05-07 | -$0.59 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$0.85 derived: net income ÷ weighted average shares · filed 2026-05-07 | ||
| 2024-12-31 | -$0.31 10-K · filed 2026-03-23 | -$0.57 derived: net income ÷ weighted average shares · filed 2026-03-23 | -$1.15 10-K · filed 2026-03-23 | ||
| 2024-09-30 | -$0.26 10-K · filed 2026-03-23 | -$0.84 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | -$0.34 10-K · filed 2026-03-23 | -$0.58 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | -$0.24 10-K · filed 2026-03-23 | ||||
| 2023-12-31 | -$0.17 10-K · filed 2025-03-07 | -$1.00 10-K · filed 2025-03-07 | |||
| 2023-09-30 | -$0.17 10-K · filed 2025-03-07 | -$0.81 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$0.28 10-K · filed 2025-03-07 | -$0.63 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$0.35 10-K · filed 2025-03-07 | ||||
| 2022-12-31 | -$0.15 10-K · filed 2024-03-01 | $11.85 10-K · filed 2024-03-01 | |||
| 2022-09-30 | $12.14 10-K · filed 2024-03-01 | $11.66 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | -$0.11 10-K · filed 2024-03-01 | -$0.45 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | -$0.34 10-K · filed 2024-03-01 | -$0.65 10-Q · filed 2022-05-06 | |||
| 2021-12-31 | -$0.43 10-K · filed 2023-03-01 | -$2.87 10-K · filed 2023-03-01 | |||
| 2021-09-30 | -$0.48 10-K · filed 2023-03-01 | -$2.46 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | -$0.80 10-K · filed 2023-03-01 | -$2.03 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | -$1.24 10-K · filed 2023-03-01 | ||||
| 2020-12-31 | -$0.92 10-K · filed 2022-02-28 | -$4.46 10-K · filed 2023-03-01 | |||
| 2020-09-30 | -$1.16 10-K · filed 2022-02-28 | -$3.55 10-Q · filed 2021-11-08 | |||
| 2020-06-30 | -$1.00 10-K · filed 2022-02-28 | ||||
| 2020-03-31 | -$1.40 10-K · filed 2022-02-28 | ||||
| 2019-12-31 | -$4.25 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |